Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma

BACKGROUND: Sunitinib is an approved treatment for metastatic renal cell carcinoma (mRCC). The safety profile and efficacy of sunitinib were confirmed in a global expanded access trial (ClinicalTrials.gov identifier: NCT00130897). This report presents a subanalysis of the final trial data from patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrios, Carlos H, Herchenhorn, Daniel, Chacón, Matías, Cabrera-Galeana, Paula, Sajben, Peter, Zhang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045222/
https://www.ncbi.nlm.nih.gov/pubmed/27713637
http://dx.doi.org/10.2147/OTT.S109445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045222/
https://www.ncbi.nlm.nih.gov/pubmed/27713637
http://dx.doi.org/10.2147/OTT.S109445

Ejemplares similares